Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

UCI Health medical oncologist Poorva Vaidya, MD is currently offering a new clinical trial sponsored by the UC Irvine Anti-Cancer Challenge, and lead by Warren Chow, MD, aimed at tackling a persistent challenge in melanoma care if patients fail first-line immunotherapy.

June 24, 2026

UCI Health

1

A new clinical trial is being conducted to explore adding low-dose oral chemotherapy to immunotherapy for melanoma patients.
2

The trial is led by Warren Chow, MD, and sponsored by the UC Irvine Anti-Cancer Challenge.
3

The study focuses on patients who have progressed after first-line immunotherapy treatment.
4

Cyclophosphamide is the chemotherapy drug being tested in a continuous regimen to combat resistance.
5

Results from the trial may provide insights by ASCO 2027 to enhance treatment options for melanoma patients.

Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

1

2

3

4

5

Original Source(s)

Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

Related Content

Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

What Medicare Claims Tell Us About Cancer Disparities in American Indian and Alaska Native Peoples